Madrigal Pharmaceuticals Stock - weekly review and NASH sector context
19.06.2026 - 18:39:22 | ad-hoc-news.de
Edited by ad hoc news Sector & Peer-Group Desk. Verified prior to publication on 06/19/2026, 16:30 UTC. Details in the imprint.
Madrigal Pharmaceuticals (US5563691094) focuses this week on how its NASH franchise stacks up against liver-disease peers after an FDA approval earlier this year. Investors are reviewing how the stock trades relative to other metabolic and liver names in the biotech sector.
All news and analysis on Madrigal Pharmaceuticals stock
Background, filings and market data help frame how Madrigal Pharmaceuticals stock trades within the competitive NASH and biotech peer group.
How the NASH week looked
The core story around Madrigal this week remains its position as the first company with an approved therapy for nonalcoholic steatohepatitis, now called metabolic dysfunction-associated steatohepatitis (MASH), in the United States following FDA approval of resmetirom in March 2024.
That decision made resmetirom, marketed as Rezdiffra, the first drug authorized in the U.S. to treat MASH with moderate to advanced liver fibrosis, and set a commercial and regulatory benchmark for others in the space.
Peer-group and sector backdrop
The broader biotech sector has seen shifting sentiment this week as investors rotate between large-cap and mid-cap names, with liver and metabolic disease players often moving together on macro news such as interest rate expectations and risk appetite.
Within liver disease, Madrigal sits alongside other companies pursuing NASH and related indications, including firms studying GLP-1-based approaches and combination regimens, even though exact competitive names differ by mechanism and development stage.
How the company makes money
Madrigal Pharmaceuticals is a clinical-stage biotech transitioning into a commercial company, centered on resmetirom, an oral thyroid hormone receptor beta-selective agonist designed to treat MASH and potentially other metabolic and liver conditions.
Revenues will initially be driven by U.S. sales of Rezdiffra to hepatologists and specialists treating patients with biopsy-proven MASH and fibrosis, with international expansion and label extensions as potential medium-term growth drivers.
Where the stock trades today
Madrigal Pharmaceuticals stock trades on Nasdaq under the ticker MDGL; the most recent verifiable quote from public market data shows the shares changing hands on Nasdaq in U.S. dollars, with the latest price information subject to intra-day updates by the exchange.
Key facts on Madrigal Pharmaceuticals stock
- Company: Madrigal Pharmaceuticals Inc.
- ISIN: US5563691094
- WKN: A2APZ9
- Ticker: MDGL
- Venue: Nasdaq
- Market cap: Market capitalization is determined by Nasdaq based on the prevailing MDGL share price and share count and fluctuates with trading.
- Sector / Industry: Health Care / Biotechnology
- Index membership: Madrigal is a component of selected biotech and health-care indices and ETFs, but not of the Standard & Poor's 500 index.
- Next earnings date: The next quarterly earnings release date has not been officially scheduled on the company’s investor-relations calendar.
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
